National Psoriasis Foundation

Sep 12, 2017

DermTech Appoints Gerald Krueger, MD, to Scientific Advisory Board

Sep 11, 2017

Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress

Aug 01, 2017

Psoriasis Action Month -- Set Goals, Take Control

Jun 27, 2017

OWC Pharmaceutical Research Corp. Announces Market Readiness of its Cannabinoid-based Topical Cream for Skin Conditions Starting With Psoriasis

Jun 26, 2017

Psoriasis Registry Reaches Milestone, Enrolls its 3,000th patient

Jun 16, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

Jun 15, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

May 31, 2017

OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts